Literature DB >> 626496

Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin.

J Sjövall, L Magni, T Bergan.   

Abstract

Bacampicillin, a new oral prodrug which in vivo is rapidly transformed to ampicillin, was compared with ampicillin, pivampicillin, and amoxycillin in a randomized cross-over study on 11 healthy volunteers. All drugs were given in oral doses equimolar to 400 mg of bacampicillin (800 mumol). The mean of the individual peak concentrations in serum was 8.3 mug/ml for bacampicillin, 7.1 mug/ml for pivampicillin, 7.7 mug/ml for amoxycillin, and 3.7 mug/ml for ampicillin. Furthermore, bacampicillin had a higher absorption rate than all the other drugs, although there were statistically significant differences only versus ampicillin. The peak serum levels of the individual subjects were more dispersed with ampicillin and amoxycillin, suggesting a more uniform absorption of bacampicillin and pivampicillin. The relative bioavailability of bacampicillin and pivampicillin was comparable, whereas ampicillin was only 2/3 that of the others.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626496      PMCID: PMC352190          DOI: 10.1128/AAC.13.1.90

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin.

Authors:  M Rozencweig; M Staquet; J Klastersky
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

2.  BRL.8988 (talampicillin), a well-absorbed oral form of ampicillin.

Authors:  J P Clayton; M Cole; S W Elson; H Ferres
Journal:  Antimicrob Agents Chemother       Date:  1974-06       Impact factor: 5.191

3.  Studies on the relationship of tissue fluid and blood levels of penicillin.

Authors:  L WEINSTEIN; G K DAIKOS; T S PERRIN
Journal:  J Lab Clin Med       Date:  1951-11

4.  Problems associated with analysis of pharmacokinetic models.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

Review 5.  Pharmacokinetics of the penicillins in man.

Authors:  M Barza; L Weinstein
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 6.  Practical concepts of drug absorption, distribution and loss.

Authors:  C MacLeod; H Rabin; R Ogilvie; J Ruedy; M Caron; D Zarowny; R O Davies
Journal:  Can Med Assoc J       Date:  1974-08-17       Impact factor: 8.262

7.  Pharmacokinetics of pivampicillin and ampicillin in man.

Authors:  J C Loo; E L Foltz; H Wallick; K C Kwan
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

8.  Pharmacological and clinical study of bacampicillin in acute peritonsillitis--a comparison with ampicillin.

Authors:  H O Hallander; A Flodström; J Sjövall
Journal:  Antimicrob Agents Chemother       Date:  1977-02       Impact factor: 5.191

9.  Amoxicillin: in vitro and pharmacological studies.

Authors:  G P Bodey; J Nance
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

10.  Sensitivity of Haemophilus influenzae to antibiotics.

Authors:  J D Williams; J Andrews
Journal:  Br Med J       Date:  1974-01-26
View more
  24 in total

Review 1.  Variations in amoxicillin pharmacokinetic/pharmacodynamic parameters may explain treatment failures in acute otitis media.

Authors:  Michael E Pichichero; Michael D Reed
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

2.  Potential improvement in the shelf life of parenterals using the prodrug approach: bacampicillin and talampicillin hydrolysis kinetics and utilization time.

Authors:  N A Nguyen; L M Mortada; R E Notari
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200

3.  Potential improvement in shelf life using the prodrug approach. II. A systematic examination of kinetic requirements.

Authors:  N A Nguyen; R E Notari
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

4.  Clinical pharmacological evaluation of aminopenicillins.

Authors:  H Mattie; P L Meenhorst
Journal:  Infection       Date:  1979       Impact factor: 3.553

5.  Pharmacokinetic study of lenampicillin (KBT-1585) in healthy volunteers.

Authors:  A Saito; M Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 6.  [Fifty years of penicillins. A review of structure-effect relationships of beta-lactamase antibiotics and their microbiological and clinical relevance (author's transl)].

Authors:  A Dalhoff
Journal:  Infection       Date:  1979       Impact factor: 3.553

Review 7.  Prodrugs. Do they have advantages in clinical practice?

Authors:  V J Stella; W N Charman; V H Naringrekar
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

Review 8.  Pharmacokinetics of bacampicillin tablets in adults.

Authors:  W A Craig
Journal:  Bull N Y Acad Med       Date:  1983-06

9.  Pharmacokinetics of bacmecillinam and pivmecillinam in volunteers.

Authors:  K Josefsson; T Bergan; L Magni; B G Pring; D Westerlund
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Comparative clinical pharmacology of bacampicillin and high oral doses of ampicillin.

Authors:  L Magni; J Sjövall; E Syvälahti
Journal:  Infection       Date:  1978       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.